November 30, 2015


Xarelto (generic name rivaroxaban) is a new-generation anticoagulant that was approved in 2011. Manufactured by Bayer and marketed in the United States by Johnson and Johnson, it is one of the newest blood thinners on the market used to reduce the risk of strokes and blood clots. It is marketed as being easier to use than warfarin as it does not require medical monitoring. The blood of a patient on warfarin is periodically checked to assess if warfarin levels are appropriate, and then adjusted if needed. This type of monitoring is not done with a patient on Xarelto and it is this ease of use that is used to “sell” the drug.
The most dangerous side effect of Xarelto is uncontrollable bleeding (hemorrhaging), and unlike warfarin, a trusted blood thinner for the past 50 years, Xarelto has no antidote to stop the bleeding when it occurs, which can be fatal. Lawsuits filed by those injured while on the drug or filed by family members who have lost a loved one, state that sufficient warnings were not given to them about the risks of Xarelto.
Other side effects and injuries that have led patients and their families to file a lawsuit against the makers of Xarelto include:
• Brain hemorrhaging
• Retinal hemorrhaging
• Intestinal bleeding
• Blood clots
• Embolism
• Stroke
• Decrease in haemoglobin
• Deep vein thrombosis
• Pulmonary embolism
• Gastrointestinal hemorrhaging

One of the less publicized issues with Xarelto is wound leakage and infection following surgery for hip or knee replacements. Xarelto increases wound leakage and infection by more than 10 times and this complication often sends patients back in to surgery. Because of this risk, surgeons are prescribing alternate drugs and methods such as Aspirin and compression stockings.

Filing a lawsuit is oftentimes the only way drug companies are held accountable for manufacturing dangerous drugs and withholding vital information about the drug, such as there is no antidote. Bayer and Johnson and Johnson promoted the benefits of the medication but severely minimized the information about its risks.
The first Xarelto lawsuit due to excessive bleeding was filed against Bayer and Johnson and Johnson in 2014 with the expected trial dates set for 2016. As of 2015, there have been no confirmed reports of any monetary settlements from the makers of Xarelto.
By mid-2015 there were around 2000 cases involving Xarelto litigation. Before settlement negotiations can begin a substantial amount of pretrial litigation has to be completed. The complaints against the drug makers involve similar allegations, in that they failed to properly research the bleeding risks of Xarelto and did not adequately warn about the lack of an effective reversal agent allowing doctors to control bleeding should it develop among those who use it.
If you or a loved one was affected with uncontrolled bleeding or any of the other dangerous side effects of Xarelto you may have legal options and our lawyers are here to help you.

Lisa Caricato

About Lisa Caricato


Leave a Comment